Anti-inflammatory Cells in Peritoneal Cavity

NCT03189316 | Terminated

• 1 other identifier: 9828
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

Some subsets of lymphocytes are able to inhibit immune response and thus, could be used to control auto-immune diseases and transplant reject. In mice, the main source of those anti-inflammatory lymphocytes is the peritoneal cavity. No data are available in human. This study aims at exploring the presence of those anti-inflammatory lymphocytes in human peritoneal cavity and at determine how to expand those cells.

Conditions

Ovarian Cysts; Chronic Renal Insufficiency

Keywords

Peritoneal fluid; B cells; Regulatory B cells; Human

Outcome Measures

Primary Outcomes (1)

• relative percentage of regulatory B cells among B cells in peritoneal cavity compared to peripheral blood

  Comparison of Breg cell in peritoneal cavity to Breg cell in peripheral blood B

  up to 48 hour

Study Arms (2)

subjects with ovarian cyst

OTHER

Peritoneal fluid sample obtained from coelioscopy for exploration of ovarian cysts and blood sample

Other: peritoneal fluid and blood sample

subjects with peritoneal dialysis

OTHER

Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample

Other: peritoneal fluid and blood sample

Interventions

peritoneal fluid and blood sample OTHER

Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample or Peritoneal fluid obtained from coelioscopy for exploration of ovarian cysts and blood cell

subjects with ovarian cyst; subjects with peritoneal dialysis

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• woman over 18 year old undergoing exploration of ovarian cysts by coelioscopy
• patient with chronic renal insufficiency undergoing peritoneal dialysis
• informed consent obtained

You may not qualify if:

• pregnancy or breast-feeding
• non affiliation to health care insurance
• treatment with corticosteroids over 15 mg/day
• treatment with rituximab

Sponsors & Collaborators

• University Hospital, Montpellier: lead
• Centre National de la Recherche Scientifique, France: collaborator

Study Sites (1)

CHU montpellier - department of rheumatology

Montpellier, 34295, France

Location

MeSH Terms

Conditions

Ovarian Cysts; Renal Insufficiency, Chronic

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Cysts; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Gonadal Disorders; Endocrine System Diseases; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 30, 2017
• First Posted: June 16, 2017
• Study Start: June 6, 2017
• Primary Completion: December 13, 2017
• Study Completion: December 13, 2017
• Last Updated: June 13, 2018

Record last verified: 2018-06

Locations

FR (1)